{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:21:05Z","timestamp":1786119665857,"version":"build-2736575974"},"reference-count":18,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,2]]},"DOI":"10.1097\/ftd.0b013e3182031021","type":"journal-article","created":{"date-parts":[[2010,12,14]],"date-time":"2010-12-14T03:59:46Z","timestamp":1292299186000},"page":"21-24","source":"Crossref","is-referenced-by-count":36,"title":["Effects of the CYP2D6*10 Allele on the Steady-State Plasma Concentrations of Aripiprazole and Its Active Metabolite, Dehydroaripiprazole, in Japanese Patients With Schizophrenia"],"prefix":"10.1097","volume":"33","author":[{"given":"Takeshi","family":"Suzuki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuo","family":"Mihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akifumi","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Goyo","family":"Nagai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shoko","family":"Kagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Nemoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ikuya","family":"Ohta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hajime","family":"Arakaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsukasa","family":"Uno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsuyoshi","family":"Kondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-4-20210129","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1038\/sj.npp.1300203","article-title":"Arrington E, at al. Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology.","volume":"28","author":"Shapiro","year":"2003","journal-title":"Neuropsychopharmacology"},{"key":"R2-4-20210129","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.2165\/00003495-200464150-00010","article-title":"Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder.","volume":"64","author":"Harrison","year":"2004","journal-title":"Drugs"},{"key":"R3-4-20210129","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.eurpsy.2007.03.002","article-title":"A multicentre, randomized, naturalistic, open-label study between aripiprazole and standard of care in the management of community-treated schizophrenic patients Schizophrenia Trial of Aripiprazole (STAR) study.","volume":"22","author":"Kerwin","year":"2007","journal-title":"Eur Psychiatry"},{"key":"R4-4-20210129","doi-asserted-by":"crossref","first-page":"612","DOI":"10.2174\/138920007781368908","article-title":"N-dealkylation of arylpiperazine derivatives: disposition and metabolism of the 1-aryl-piperazines formed.","volume":"8","author":"Caccia","year":"2007","journal-title":"Curr Drug Metab"},{"key":"R5-4-20210129","doi-asserted-by":"crossref","first-page":"55","DOI":"10.2133\/dmpk.20.55","article-title":"Influence of itraconazole co-administration and CYP2D6 genotype on the pharmacokinetics of the new antipsychotic aripiprazole.","volume":"20","author":"Kubo","year":"2005","journal-title":"Drug Metab Pharmacokinet"},{"key":"R6-4-20210129","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1046\/j.0306-5251.2001.01548.x","article-title":"Molecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugs.","volume":"53","author":"Bertilsson","year":"2002","journal-title":"Br J Clin Pharmacol"},{"key":"R7-4-20210129","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1097\/00008571-199508000-00005","article-title":"Detection of the poor metabolizer-associated CYP2D6(D) gene deletion allele by long-PCR technology.","volume":"5","author":"Steen","year":"1995","journal-title":"Pharmacogenetics"},{"key":"R8-4-20210129","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1046\/j.1365-2125.2000.00209.x","article-title":"Frequencies of CYP2D6 mutant alleles in a normal Japanese population and metabolic activity of dextromethorphan O-demethylation in different CYP2D6 genotypes.","volume":"50","author":"Kubota","year":"2000","journal-title":"Br J Clin Pharmacol"},{"key":"R9-4-20210129","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/S0026-895X(25)09721-4","article-title":"Genetic analysis of the Chinese cytochrome P4502D locus: characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation.","volume":"46","author":"Johansson","year":"1994","journal-title":"Mol Pharmacol"},{"key":"R10-4-20210129","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1111\/j.1365-2125.2008.03223.x","article-title":"Population pharmacokinetic modelling of aripiprazole and its active metabolite, dehydroaripiprazole, in psychiatric patients.","volume":"66","author":"Kim","year":"2008","journal-title":"Br J Clin Pharmacol"},{"key":"R12-4-20210129","doi-asserted-by":"crossref","first-page":"2460","DOI":"10.1124\/dmd.108.023242","article-title":"Functional characterization of 17 CYP2D6 allelic variants (CYP2D6.2, 10, 14A-B, 18, 27, 36, 39, 47-51, 53-55, and 57).","volume":"36","author":"Sakuyama","year":"2008","journal-title":"Drug Metab Dispos"},{"key":"R13-4-20210129","doi-asserted-by":"crossref","first-page":"358","DOI":"10.2133\/dmpk.22.358","article-title":"Pharmacokinetics of aripiprazole, a new antipsychotic, following oral dosing in healthy adult Japanese volunteers: influence of CYP2D6 polymorphism.","volume":"22","author":"Kubo","year":"2007","journal-title":"Drug Metab Pharmacokinet"},{"key":"R14-4-20210129","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.jchromb.2005.06.023","article-title":"Development and validation of an LC-MS\/MS method for the quantitative determination of aripiprazole and its main metabolite, OPC-14857, in human plasma.","volume":"822","author":"Kubo","year":"2005","journal-title":"J Chromatography B"},{"key":"R15-4-20210129","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1007\/s00228-007-0373-6","article-title":"Impact of the CYP2D6 genotype on steady-state serum concentrations of aripiprazole and dehydroaripiprazole.","volume":"63","author":"Hendset","year":"2007","journal-title":"Eur J Clin Pharmacol"},{"key":"R16-4-20210129","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1111\/j.1440-1819.2008.01907.x","article-title":"Long-term efficacy and safety of aripiprazole in patients with schizophrenia, schizophreniform disorder, or schizoaffective disorder: 26-week prospective study.","volume":"63","author":"Kwon","year":"2009","journal-title":"Psychiatry Clin Neurosci"},{"key":"R17-4-20210129","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S0009-9236(99)70108-6","article-title":"Effects of the CYP2D6*10 al10 allele on the steady-state plasma concentrations of haloperidol and reduced haloperidol in Japanese patients with schizophrenia.","volume":"65","author":"Mihara","year":"1999","journal-title":"Clin Pharmacol Ther"},{"key":"R18-4-20210129","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1097\/00007691-200306000-00006","article-title":"Effects of various CYP2D6 genotypes on the steady-state plasma concentrations of risperidone and its active metabolite, 9-hydroxyrisperidone, in Japanese patients with schizophrenia.","volume":"25","author":"Mihara","year":"2003","journal-title":"Ther Drug Monit"},{"key":"R19-4-20210129","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1097\/FTD.0b013e3181b6326a","article-title":"Pharmacokinetic and pharmacodynamic interactions between carbamazepine and aripiprazole in patients with schizophrenia.","volume":"31","author":"Nakamura","year":"2009","journal-title":"Ther Drug Monit"}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/FTD.0b013e3182031021","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T18:52:18Z","timestamp":1786042338000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00007691-201102000-00004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,2]]},"references-count":18,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0b013e3182031021","relation":{},"ISSN":["0163-4356"],"issn-type":[{"value":"0163-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2011,2]]}}}